Now showing items 1-4 of 4
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults
(Oxford University Press, 2008-07-19)
Background: We aimed to compare the steady-state pharmacokinetic parameters and tolerability of Triomune 40w (stavudine 40 mg, lamivudine 150 mg and nevirapine 200 mg) and branded formulations of these drugs in HIV-infected ...
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
(Oxford University Press, 2012)
Objectives: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz ...
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
(Journal of Antimicrobial Chemotherapy, 2012-02-08)
Background: Treatment of HIV/malaria-coinfected patients with antiretroviral therapy (ART) and artemisininbased combination therapy has potential for drug interactions. We investigated the pharmacokinetics of artemether, ...
Artemether-Lumefantrine combination therapy for treatment of uncomplicated malaria: The potential for complex interactions with antiretroviral drugs in HIV-infected individuals
(Malaria Research and Treatment, 2011-02-14)
Treatment of malaria in HIV-infected individuals receiving antiretroviral therapy (ART) poses significant challenges. Artemether-lumefantrine (AL) is one of the artemisisnin-based combination therapies recommended for ...